Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.050
+0.030 (2.94%)
At close: Mar 28, 2025, 4:00 PM
1.021
-0.030 (-2.81%)
After-hours: Mar 28, 2025, 7:50 PM EDT
Barinthus Biotherapeutics Revenue
In the year 2024, Barinthus Biotherapeutics had annual revenue of $14.97M with 1,766.46% growth.
Revenue (ttm)
$14.97M
Revenue Growth
+1,766.46%
P/S Ratio
2.76
Revenue / Employee
$115,146
Employees
130
Market Cap
42.36M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BRNS News
- 10 days ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 24 days ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 2 months ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 4 months ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire
- 4 months ago - Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion - GlobeNewsWire
- 4 months ago - Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B - GlobeNewsWire
- 5 months ago - Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewsWire
- 10 months ago - Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewsWire